title: Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression.
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Mehmet E
authors.initials: ME
authors.lastname: Tezcan
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozen
authors.forename: Fatih
authors.initials: F
authors.lastname: Karaahmet
authors.forename: Nilufer
authors.initials: N
authors.lastname: Bulut
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001940:Breast / Q000187:drug effects / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D015552:Injections, Intralesional; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab